Development of selective human DHODH inhibitors for antiviral therapy

Vol 2, 2022 - 153240
Poster
Favoritar este trabalho
Como citar esse trabalho?
Resumo

The human dihydroorotate dehydrogenase (hDHODH), a crucial flavin-dependent mitochondrial enzyme in the de novo pyrimidine synthesis, has been considered a promising therapeutic target to tackle tumor progression and viral infection since infectious viruses such as the SARS-CoV-2, a current global threat to public health,
require host factors including hDHODH for viral replication. Therefore, the development of selective hDHODH inhibitors as host-targeting antivirals (HTAs) may lead to effective broad-spectrum antiviral agents with minimal drug resistance induction as an alternative to Leflunomide, Teriflunomide, and Brequinar, which have known efficacy and toxicity issues. Based on the interaction profile of quinone-based molecules in the ubiquinone binding site of hDHODH, we rationalized that the heterocyclic scaffolds quinazolinone and quinoxalinone
could mimic important hydrogen-bonding interactions. Two linear synthetic routes were successfully established to obtain functionalized quinazolinones and quinazolinones which are under evaluation via enzymatic assays with hDHODH.

Compartilhe suas ideias ou dúvidas com os autores!

Sabia que o maior estímulo no desenvolvimento científico e cultural é a curiosidade? Deixe seus questionamentos ou sugestões para o autor!

Faça login para interagir

Tem uma dúvida ou sugestão? Compartilhe seu feedback com os autores!

Instituições
  • 1 Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP), Universidade de São Paulo (USP)
  • 2 Universidade de São Paulo
Eixo Temático
  • 2. Medicinal Chemistry of Synthetic Compounds
Palavras-chave
drug design
Human DHODH
antiviral activity
Quinazolinones
Quinoxalinones